目的　评价188Re 硫化铼混悬液用于介入治疗肝癌的可能性。方法　 30只荷人SMMC 772 1肝癌细胞株的裸鼠肿瘤内分别注射188Re 硫化铼混悬液和188Re NaReO4 溶液 ,进行生物分布研究。另 30只平均分成 6组 ,其中 4组分别注射 0 1mL的 3 7、7 4、18 5、2 9 6MBq的188Re 硫化铼混悬液 ;余下 2组作为对照组注射非放射性硫化铼混悬液和生理盐水。 6d后重复注射。结果　注射188Re 硫化铼混悬液的裸鼠 ,肿瘤内放射性摄取率 (%ID) 1h为 (90 96± 6 6 3) % ,2 4h为 (86 0 9± 2 2 5 8) % ,48h为 (87 6 2± 13 97) % ,高于正常组织。而注射188Re NaReO4 溶液的裸鼠 ,肿瘤内 %ID 1h为 (1 6 6± 0 35 ) % ,2 4h为 (0 0 2± 0 0 1) % ,48h为 (0 0 1± 0 0 1) % ,和正常组织无多大区别。当肿瘤边缘 (距肿瘤中心约 0 5～ 0 6cm)的吸收剂量为 5 0 7 6Gy时 ,肿瘤抑制率可达 89%。结论　188Re 硫化铼混悬液是有希望的肝癌治疗剂 Objective To evaluate the feasibility of 188Re rhenium sulfide suspension for interventional treatment of liver cancer. Methods Biodistribution of 188Re rhenium sulfide suspension and 188Re NaReO4 solution were injected into the tumor of nude mice of 30 human SMMC 772 1 hepatocellular carcinoma cell lines respectively. The other 30 rats were equally divided into 6 groups, of which 4 groups were injected with 0 1mL of 3,7,7 4,18 5,2 9 6MBq of 188Re rhenium sulfide suspension; the remaining 2 groups were injected as a control group of non-radioactive rhenium sulfide suspension And saline. 6d after repeated injections. Results In nude mice injected with 188Re rhenium suspension, the in vivo radioactive uptake rate (% ID) was (90 96 ± 6 6 3)% for 1 h, (86 0 9 ± 2 2 58)% for 24 h, (87 6 2 ± 13 97)%, higher than normal tissues. In nude mice injected with 188Re NaReO4 solution, the% ID 1h in the tumor was (166 ± 0 35)%, the rate was (0 0 2 ± 0 0 1)% at 24 hours and (0 0 1 ± 0 0 1) %, And no much difference between normal tissue. When the tumor edge (from the tumor center about 0 5 ~ 0 6cm) absorbed dose of 5 0 7 6Gy, the tumor inhibition rate up to 89%. Conclusion 188Re rhenium sulfide suspension is a promising therapeutic agent for liver cancer